Previous 10 | Next 10 |
Company to launch OSPREY investigational device exemption clinical study in the U.S. LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to proceed w...
NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of ...
Additional local business closings to occur later this year LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed the initial closing of the divestiture of its heart valve (HV) business to Gy...
The leading player in the market for blood plasma collection equipment. The plasma market is a duopoly with Fresenius in a distant number two position. Recent price weakness represents a significant opportunity to own a good quality leader at a very good price. The market has over...
Haemonetics shares have been punished since April on the back of CSL Plasma's decision not to renew the use of PCS2 from June 2022. Shares immediately saw a gap-fill to the downside and have shown downward pressures since, however, fundamentally little has changed. Theoretically ~...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 8 a.m. Eastern Time. The discussion will be available ...
LivaNova Plc continues its excellent turnaround story that commenced in October 2020, since 2.2% owner Prime Capital LLP's scathing letter. Shareholders have enjoyed +65% upside from this point until today, and the technical picture corroborates more upside on the charts. We are l...
LivaNova PLC (LIVN) Q1 2021 Earnings Conference Call April 28, 2021 7:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development Damien McDonald - Chief Executive Officer Alex Shvartsburg - Interim Chief Financial Officer Melissa Farina - Vice President of In...
The following slide deck was published by LivaNova PLC in conjunction with their 2021 Q1 earnings call. For further details see: LivaNova PLC 2021 Q1 - Results - Earnings Call Presentation
After a post-earnings rally yesterday, one healthcare equipment company reached up and touched $90/share, for just a minute - and "stocks that go to $90 tend to go to $100," or so the aphorism goes, Baird notes. But $100 is its new price target for LivaNova (LIVN), which closed Wednesday up 4...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. ...
2024-06-06 11:00:14 ET Rick Wise from Stifel Nicolaus issued a price target of $70.00 for LIVN on 2024-06-06 09:52:00. The adjusted price target was set to $70.00. At the time of the announcement, LIVN was trading at $53.16. The overall price target consensus is at $69.5...